After the delayed interest rate hike by the Bank of Japan, the Nikkei average stock price temporarily recovered to 36,500 yen.
The Nikkei average continued to rise significantly for six consecutive trading days, closing up 406.92 yen at 36,452.30 yen (Volume estimated at 1.8 billion 60 million shares). Amid the sharp surge in the after-hours trading of U.S. Microsoft and Meta Platforms Inc, buying started to lead in the Tokyo market, particularly in the Semiconductors sector. Additionally, the depreciation of the yen to the 144 yen level against the dollar following the announcement of the Bank of Japan's monetary policy decision was also viewed as favorable, increasing the number of export-related stocks that gained in value.
Koei Tecmo, Komeda ETC (addition) Rating
Upgrade - Bullish Code Stock Name Brokerage Firm Previous After---------------------------------------------------- <8968> Fukuoka REIT Mizuho "Hold" "Buy" Downgrade - Bearish Code Stock Name Brokerage Firm Previous After---------------------------------------------------- <3481> Mitsubishi Logistics Mizuho "Buy" "Hold" <7752> Ricoh Daiwa
Kyowa Kirin, Mitsui & Co., Sumitomo Corp., Yamato HD (on the 1st).
※ The above Calendar is merely a schedule and may be subject to change due to the company's circumstances.--------------------------------------- May 1 (Thursday) <2148> ITM <2551> Marusan Ai <2579> Coca BJH <2768> Sojitz <299A> dely <3064> MonotaRO <4151> Kyowa Kirin <4206> Ai
Emerging Markets split candidate stocks [Emerging Markets split candidate stocks]
Code Name of stock <338A> Zenmu <4393> Bank of Innovation <6026> GMO TECH <3496> Azum <2986> LAHD <4894> Quolips <278A> Terra Drone <4417> Global Security <350A> Digital Grid <4051> GMO-FG <2998> Clear.
Chordia --- significantly dropped, development halted for the inhibitor of the mucosal-associated lymphoid tissue lymphoma translocation protein 1.
Significantly declined. It has been announced that the strategic licensing partner, Ono Pharmaceutical Co., Ltd. <4528>, has decided to cease the development of the Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) inhibitor "CTX-177" for strategic reasons and return the rights related to its development, manufacturing, and commercialization to Chordia Therapeutics. Going forward, discussions will be held with Ono Pharmaceutical regarding the termination of the licensing agreement, and options will be considered.
Stocks hitting the upper and lower limits before the market.
■ Limit up <4240> Cluster Technology <4506> Sumitomo Pharma ■ Limit down <6836> Plat Home *Includes temporary limit up and down (indicative prices).